by Sucralfate is primarily used to treat ulcers in the stomach and gastrointestinal tract. It forms an artificial protective covering over the areas of ulcers to protect the ulcer from acid and prevents the breakdown of ulcer tissue.
The global U.S. Sucralfate Market is estimated to be valued at US$ 60.8 Mn in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising prevalence of gastrointestinal ulcers and disorders such as gastritis, reflux esophagitis has led to the surge in demand for sucralfate for treatment. According to the Centers for Disease Control and Prevention reports, approximately 20% of the U.S population suffers from gastrointestinal issues like ulcers each year. The statistic shows huge clinical potential of sucralfate in gastrointestinal problems driving the U.S sucralfate market in forecast period.
SWOT Analysis
Strength: Sucralfate is a very effective drug for the treatment of various stomach ulcers with a good safety profile. It acts locally on affected areas and protects gastric mucosa from acid and pepsin damage.
Weakness: Sucralfate needs to be administered multiple times in a day and adherence to dosage schedule can be challenging for some patients. Its effectiveness also depends on the ability to maintain adequate concentration at ulcer sites.
Opportunity: Rising prevalence of peptic ulcers across all age groups presents an opportunity for sucralfate manufacturers. Increasing awareness about gastrointestinal disorders can boost the sucralfate market.
Threats: Presence of alternative treatment options like PPIs (Proton pump inhibitors) poses competition in the market. Generic versions erode brand loyalty and impact sales of established sucralfate brands.
Key Takeaways
The U.S. Sucralfate Market Size is expected to witness high growth, exhibiting CAGR of 4.2% over the forecast period, due to increasing prevalence of peptic ulcers in the country. It is estimated that over 5 million Americans suffer from peptic ulcers annually. Sucralfate is predominantly used for treating various gastric and duodenal ulcers.
Regional analysis: The Northeast region holds a significant share in the U.S sucralfate market due to presence of major pharmaceutical companies. However, the Southern region is expected to witness fastest growth due to growing elderly population who are at a higher risk of developing ulcers.
Key players operating in the U.S. Sucralfate market are Sanofi, Teva Pharmaceutical Industries, Taro Pharmaceuticals, Mylan N.V., and Perrigo Company PLC. Sanofi’s Carafate (sucralfate) suspension leads the market and the company invests heavily in promotion and branding of the product. Teva Pharmaceuticals offers sucralfate tablets under various generic labels.
